72370-19-5

Basic information

• Product Name: 5-(bromoacetyl)-2-(phenylmethoxy)benzamide
• Synonyms: 5-(bromoacetyl)-2-(phenylmethoxy)benzamide;5-(2-Bromoacetyl)-2-(phenylmethoxy)benzamide;Labeint-A5
• CAS NO: 72370-19-5
• Molecular Formula: C₁₆H₁₄BrNO₃
• Molecular Weight: 348.19126
• EINECS: 276-604-5
• Mol File: 72370-19-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 150-152 °C
• Boiling Point: 493.3°C at 760 mmHg
• Flash Point: 252.1°C
• Appearance: /
• Density: 1.465g/cm³
• Vapor Pressure: 7.12E-10mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 14.87±0.50(Predicted)
• CAS DataBase Reference: 5-(bromoacetyl)-2-(phenylmethoxy)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(bromoacetyl)-2-(phenylmethoxy)benzamide(72370-19-5)
• EPA Substance Registry System: 5-(bromoacetyl)-2-(phenylmethoxy)benzamide(72370-19-5)

Safety Data

• Hazardous Substances Data: 72370-19-5(Hazardous Substances Data)

Usage

Uses

5-(2-Bromoacetyl)-2-(phenylmethoxy)benzamide is an intermediate of (R,R)-Labetalol (L096500), a specific competitive antagonist at both α-and β-adrenergic receptor sites. (R,R)-Labetalol is used as an antihypertensive.

InChI:InChI=1/C16H14BrNO3/c17-9-14(19)12-6-7-15(13(8-12)16(18)20)21-10-11-4-2-1-3-5-11/h1-8H,9-10H2,(H2,18,20)

Upstream product

• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 40187-51-7 5-acetylsalicylamide 
• 75637-30-8 5-acetyl-2-(phenylmethoxy)benzamide 

Downstream Products

• 81602-14-4 (-)-2-hydroxy-5-<(R)-1-hydroxy-2-<(S)-(1-methyl-3-phenylpropyl)amino>ethyl>benzamide hydrochloride 
• 81602-13-3 *)>-2-hydroxy-5-<1-hydroxy-2-<(1-methyl-3-phenylpropyl)amino>ethyl>benzamide hydrochloride 
• 75615-56-4 *,R^*)>-5-<1-hydroxy-2-ethyl>-2-(phenylmethoxy)benzamide 
• 75615-55-3 *,R^*)>-5-<1-hydroxy-2-ethyl>-2-(phenylmethoxy)benzamide 
• 81585-06-0 *,S^*)>-5-<1-hydroxy-2-ethyl>-2-(phenylmethoxy)benzamide 
• 81580-37-2 *,S^*)>-5-<1-hydroxy-2-ethyl>-2-(phenylmethoxy)benzamide 
• 392620-18-7 2-(Benzyloxy)-5-(2-bromo-1-hydroxyethyl)benzamide 
• 83167-22-0 5-<<<(S)-1-methyl-3-phenylpropyl>(phenylmethyl)amino>acetyl>-2-(phenylmethoxy)benzamide 
• 75615-53-1 5-<<<(R)-1-methyl-3-phenylpropyl>(phenylmethyl)amino>acetyl>-2-(phenylmethoxy)benzamide 
• 392622-69-4 4-{4-[2-({2-[3-(Aminocarbonyl)-4-(benzyloxy)phenyl]-2-hydroxyethyl}-amino)ethyl]anilino}-N-octyl-1-piperidinecarboxamide 
• 150125-47-6 2-(benzyloxy)-5-(2-oxiranyl)benzamide 

Relevant articles and documents

HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS

This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

Synthesis and Comparison of Some Cardiovascular Properties of the Stereoisomers of Labetalol

A useful method for the separation of labetalol into its two racemic diastereomers, as well as a stereoselective synthesis of its four stereoisomers, is described.The absolute stereochemistry of each isomer was determined by analysis of the CD spectra and confirmed by X-ray analysis.The α- and β1-adrenergic blocking properties, as well as the relative antihypertensive activities, have been measured in rats.The R,R isomer, 2a (SCH 19927), possesses virtually all of the β1-blocking activity elicited by labetalol and displays little α-blocking activity.In contrast, the S,R isomer, 3a, has most of the α-blocking activity.Of the four isomers, only 2a has antihypertensive potency comparable to that of labetalol.These findings, coupled with published data showing that labetalol possesses β-adrenergic mediated peripheral vasodilating activity deriving essentially from its R,R isomer, lead to the following conclusion: The antihypertensive activity of labetalol can be ascribed to at least three identified complementary mechanisms, β-adrenergic blockade, β-adrenergic mediated vasodilatation, and α-adrenergic blockade, whereas the antihypertensive activity of 2a derives from the first two mechanisms only.